丹红注射液的临床研究进展  

Research progress of clinical application of Danhong injection

作　　者：王赏[1] 卢宏[1] WANG Shang;LU Hong(Department of Neurology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院神经内科,河南郑州450052

出　　处：《中国实用神经疾病杂志》2018年第17期1862-1866,共5页Chinese Journal of Practical Nervous Diseases

基　　金：河南省高等学校重点科研项目计划(18A320052)

摘　　要：丹红注射液(Danhong injection,DHI)是由中国的传统中药材丹参、红花提炼而得,主要有效成分是酚类化合物和黄酮类,其在传统医学领域具有活血化瘀、扩张血管、降脂、抗炎功效,因此在我国被广泛应用于临床实践中,如脑梗死、血栓形成、外伤、蛛网膜下腔出血、硬膜下血肿、眼底出血恢复期等。本文对其临床应用进展做一阐述。Danhong injection （DHI） is derived from traditional Chinese medicine Salvia miltiorrhiza and safflower from China.The main active ingredients are phenolic compounds and flavonoids.It has the functions of promoting blood circulation and expansing vascular,lipid lowering,anti inflammatory effects in traditional medicine,so it is widely used in clinical practice in China,such as cerebral infarction,thrombosis,trauma,subarachnoid hemorrhage,subdural hematoma,retinal hemorrhage recovery period.This article describes the progress of its clinical application.

关 键 词：丹红注射液 丹参酸 活血化瘀 缺血性脑卒中 出血性脑卒中 

分 类 号：R74[医药卫生—神经病学与精神病学]